Revelation Biosciences (REVB)

Executive Summary

Revelation Biosciences is a clinical-stage biopharmaceutical company headquartered in San Diego, CA, focused on developing novel immunomodulatory therapies for infectious and inflammatory diseases. Its lead candidate, GEMINI, is a proprietary innate immune system modulator designed to rebalance the inflammatory response. GEMINI has demonstrated potential in preclinical models for conditions such as acute respiratory distress syndrome (ARDS) and chronic inflammatory diseases. The company is advancing GEMINI through clinical development, with Phase 1/2 trials evaluating safety and efficacy. Revelation's strategy leverages the broad applicability of immune modulation, targeting both acute and chronic conditions with high unmet medical need. As a public company (NASDAQ: REVB), it has a modest market capitalization, reflecting early-stage risk but also significant upside potential if clinical data are positive.

Upcoming Catalysts (preview)

• Q4 2026Phase 1/2 Clinical Data Readout for GEMINI in ARDS35% success
• Q2 2027Strategic Partnership or Licensing Deal for GEMINI40% success
• Q3 2026FDA Orphan Drug Designation for GEMINI in a Chronic Inflammatory Indication60% success